The PET/CT reading physician should explore the indication for the study, PSA and Gleason score in case of primary PCa, PSA level and PSA kinetics in case of BCR, prior definitive treatments such as prostatectomy or radiation therapy, PCa-specific medications such as ADT or other androgen receptor (AR) targeted treatments, and any history of systemic chemotherapy, Radium-223 or Lutetium-177 PSMA RLT. Also, the chart should be reviewed for associated symptoms such as pain, urinary symptoms, or erectile dysfunction. The gene discussed is KLK3; the disease is posterior cortical atrophy.